Chief Executive Officer
Mr. Sullivan has over 21 years of experience working with early stage biotechnology companies and has raised over $37M in private equity and non-dilutive government funding in biotechnology. Most recently he was Chief Executive Officer at DeNovaMed Inc., a biotechnology company focused on development of Gram-negative and Gram-positive antibiotics. Previously, he was Chief Operating Officer at Viron Therapeutics, a biopharmaceutical company developing a novel immunotherapy and recipient of the Prix Galien Award for Biotechnology. At Viron, he and his team completed development of the Company’s lead program through Phase 2 clinical development with Series A and B financing from a syndicate of international venture capital including two pharma-venture participants. He is an active mentor and volunteer advisor for several start-up biotechnology companies. Mr. Sullivan received a BSc in Immunology from Dalhousie University, a Graduate Certificate in Biotechnology from McGill University and an MBA from Western University.
Chief Financial Officer
Ms. Stephens brings over 16 years of financial management experience and senior financial positions with private and public companies. Most recently, she served as CFO of Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF) from 2011-2016, where she managed the raising of more than $40 million through equity financings and government grants. Prior to joining Immunovaccine Inc., Ms. Stephens served as director of finance for the Canadian subsidiary of Germanischer Lloyd. She has also been the director of finance for SolutionInc, and started her career as an audit manager in the assurance and advisory group at PwC. Ms. Stephens holds a bachelor of commerce degree from Mount Allison University and is a chartered professional accountant (CPA).
Jamie Doran MSc, DABT, ERT
Vice President, Drug Development
Ms. Doran has over 16 years experience as a regulatory toxicologist. She has broad experience in the development, monitoring and evaluation of nonclinical studies designed to test the safety, metabolism and distribution of new products (pharmaceuticals and chemicals) entering international markets. Ms. Doran has managed and prepared pre-IND, IND and CTA submissions to the US FDA and Health Canada as well as successfully managed preclinical and clinical programs in various indications.
Vice President, Business Development
Mr. McBride has over 25 years of experience in pharmaceutical and biotech commercialization, pricing, and business development. In his role at Appili Therapeutics, Mr. McBride is responsible for all out-licensing activities, as well as leading product in-licensing and acquisition opportunities to further enhance the company’s global business.
Mr. McBride most recently served as commercial and business development lead at GlaxoSmithKline Inc. (GSK), leading a portfolio of assets valued at $170M. At GSK he was involved in all aspects of business development from lead generation to integration and divestment, including successfully completing numerous transactions with multinational pharmaceutical companies. Prior to joining GSK, Mr. McBride served as a director for healthcare agencies conducting commercial and strategic assessments in both Canada and the US and also served as director of marketing with Roche Pharmaceuticals.
Mr. McBride holds a Bachelor of Business Administration degree from Simon Fraser University and is an active member of the Canadian Healthcare Licensing Association (CHLA).